Laboratorio de Modelado Molecular y Bioinformática de la Escuela Superior de Medicina, Instituto Politécnico Nacional, México, Plan de San Luis Y Diaz Mirón S/N, Mexico city, Mexico.
Immunol Res. 2013 May;56(1):44-60. doi: 10.1007/s12026-013-8385-z.
The neuraminidase (NA) epitope from the Mexican AH1N1 influenza virus was identified by using sequences registered at the GenBank during the peak of a pandemic (from April 2009 to October 2010). First, NA protein sequences were submitted for multiple alignment analysis, and their three-dimensional models (3-D) were then built by using homology modeling. The most common sequence (denominated wild-type) and its mutants were submitted to linear and nonlinear epitope predictors, which included the major histocompatibility complex type II (MHC II) and B-cell peptides. The epitope prediction was in accordance with evolutionary behavior and some protein structural properties. The latter included a low NA mutation rate, NA 3-D surface exposure, and the presence of high hindrance side chain residues. After selecting the epitope, docking studies and molecular dynamics (MD) simulations were used to explore interactions between the epitope and MHC II. Afterward, several experimental assays were performed to validate the theoretical study by using antibodies from humans (infected by pandemic H1N1) and rabbits (epitope vaccination). The results show 119 complete sequences that were grouped into 28 protein sequences according to their identity (one wild-type and 27 representative mutants (1-5 mutations)). The predictors yielded several epitopes, with the best fit being the one located in the C-terminal region. Theoretical methods demonstrated that the selected epitope reached the P4, P6, P7, and P9 pockets of MHC II, whereas the experimental evidence indicates that the epitope is recognized by human antibodies and also by rabbit antibodies immunized with the peptide.
利用 GenBank 中在大流行高峰期(2009 年 4 月至 2010 年 10 月)注册的序列,鉴定了来自墨西哥 AH1N1 流感病毒的神经氨酸酶(NA)表位。首先,将 NA 蛋白序列提交进行多重比对分析,然后使用同源建模构建其三维模型(3-D)。最常见的序列(称为野生型)及其突变体被提交给线性和非线性表位预测器,包括主要组织相容性复合体 II 型(MHC II)和 B 细胞肽。表位预测与进化行为和一些蛋白质结构特性一致。后者包括低 NA 突变率、NA 3-D 表面暴露以及高阻碍侧链残基的存在。选择表位后,使用对接研究和分子动力学(MD)模拟来探索表位与 MHC II 之间的相互作用。此后,进行了几项实验检测,以使用来自人类(感染大流行 H1N1)和兔子(表位疫苗接种)的抗体来验证理论研究。结果显示 119 个完整序列,根据其同一性(一个野生型和 27 个代表性突变体(1-5 个突变))分为 28 个蛋白质序列。预测器产生了几个表位,最佳拟合位于 C 末端区域。理论方法表明,所选表位到达了 MHC II 的 P4、P6、P7 和 P9 口袋,而实验证据表明,该表位被人类抗体和用肽免疫的兔子抗体识别。